75 Abstracts Evaluating Celgene Products to Be Presented at The 44th American Society of Clinical Oncology Meeting

SUMMIT, N.J.--(BUSINESS WIRE)--May 16, 2008 - Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of multiple Celgene products in blood cancers and solid tumors at the 44th American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois from May 31 - June 3, 2008.

For more information and for complete abstracts, please visit www.asco.org.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.

Contact

Celgene Corporation
David W. Gryska, 908-673-9059
Senior Vice President and
Chief Financial Officer
or
Celgene Corporation
Brian P. Gill, 908-673-9530
Vice President,
Corporate Communications

Posted: May 2008

View comments

Hide
(web5)